Edition:
United States

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

1.37USD
20 Jan 2017
Change (% chg)

-- (--)
Prev Close
$1.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
314,001
52-wk High
$2.16
52-wk Low
$1.33

ARNA.OQ

Chart for ARNA.OQ

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is... (more)

Overall

Beta: -0.70
Market Cap(Mil.): $333.34
Shares Outstanding(Mil.): 243.31
Dividend: --
Yield (%): --

Financials

  ARNA.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -0.38 -- --
ROI: -47.31 -1.38 14.86
ROE: -214.07 -1.07 16.28

BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.05

* Arena Pharmaceuticals reports third quarter 2016 financial results and provides corporate update

Nov 07 2016

BRIEF-Arena Pharmaceuticals to release Q3 financial results on Nov 7

* Arena Pharmaceuticals to release third quarter 2016 financial results and provide corporate update on Monday, November 7, 2016 Source text for Eikon: Further company coverage:

Oct 31 2016

9th Circuit revives investor lawsuit over Arena weight loss drug

A federal appeals court has revived a proposed shareholder class action lawsuit accusing Arena Pharmaceuticals Inc of concealing safety concerns about its weight loss drug Belviq during its development.

Oct 27 2016

BRIEF-Eisai, Arena Pharmaceuticals announce availability of once-daily BELVIQ XR extended-release tablets

* Eisai Inc and Arena Pharmaceuticals announce availability of once-daily BELVIQ XR (lorcaserin HCI) extended-release tablets Source text for Eikon: Further company coverage:

Oct 03 2016

BRIEF-Arena Pharmaceuticals announces formation of Beacon Discovery Inc

* Announces formation of Beacon Discovery Inc, an independent, privately held drug discovery incubator

Sep 01 2016

BRIEF-Arena Pharmaceuticals, Eisai receive 'paragraph IV certification'

* Co and Eisai Inc have received a 'paragraph IV certification' notification with respect to patents for Belviq

Aug 25 2016

BRIEF-Arena Pharmaceuticals appoints Vincent Aurentz as Chief Business Officer

Aug 15 Arena Pharmaceuticals Inc : Source text for Eikon: Further company coverage:

Aug 15 2016

BRIEF-Arena Pharmaceuticals reports Q2 loss per share $0.11

* Arena Pharmaceuticals reports second quarter 2016 financial results and provides corporate update

Aug 08 2016

Competitors

Earnings vs. Estimates